Goldman Sachs downgrades Apellis stock to Sell on Syfovre growth concerns
NegativeFinancial Markets

Goldman Sachs has downgraded Apellis Pharmaceuticals' stock to 'Sell' due to concerns over the growth of its drug Syfovre. This decision reflects apprehensions about the company's future performance and market position, which could impact investor confidence and the stock's value. Understanding these shifts is crucial for stakeholders as they navigate the complexities of the pharmaceutical market.
— Curated by the World Pulse Now AI Editorial System